Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset

Blood

Volumn 91, Issue 3, 1998, Pages 852-862

  Kronenwett, Ralf ^b   Steidl, Ulrich ^b   Kirsch, Michael ^b   Sczakiel, Georg ^b   Haas, Rainer ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DI OLEOYLOXY 2 (6 CARBOXYSPERMYL)PROPYLAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CD34 ANTIGEN; INTERLEUKIN 3; INTERLEUKIN 6; LIPID; N [1 (2,3 DIOLEOYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM METHYLSULFATE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; DRUG UPTAKE; GENE THERAPY; HEMATOPOIETIC CELL; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; ISOTOPE LABELING; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032007293     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.3.852     Document Type: Article

References (56)

1. Stein CA, Chang YC: Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 261:1004, 1993
2. Crooke ST, Bennett CF: Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107, 1996
3. Wagner RW, Flanagan WM: Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 3:31, 1997
4. Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J, Gallo RC, Agrawal S: Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 91:7942, 1994
5. De Fabritiis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F: In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 9:662, 1995
6. Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB: Recent advances in the application of gene therapy to human diseases. Am J Med 99:537, 1995
7. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320, 1996
8. Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A, Ratajczak MZ: Oligodeoxynucleotide therapeutics for human myelogenous leukemia: Interim results. Blood 88:270a, 1996 (abstr, suppl 1)
9. Rittner K, Burmester C, Sczakiel G: In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1. Nucleic Acids Res 21:1381, 1993
10. Ho SP, Britton DH, Stone BA, Behrens DL, Leffet LM, Hobbs FW, Miller JA, Trainor GL: Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res 24:1901, 1996
11. Kronenwett R, Haas R, Sczakiel G: Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J Mol Biol 259:632, 1996
12. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW: Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 272:626, 1997
13. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474, 1989
14. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454, 1989
15. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814, 1995
16. Bennett CF, Chiang M-Y, Chan H, Shoemaker JEE, Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023, 1992
17. Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A: Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 197:818, 1993
18. Zhou X, Huang L: DNA transfection mediated by cationic liposomes containing lipopolylysine: Characterization and mechanism of action. Biochim Biophys Acta 1189:195, 1994
19. Lewis JG, Lin K-Y, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA Jr, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 93:3176, 1996
20. Deichmann M, Kronenwett R, Haas R: Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells. Blood 89:3522, 1997
21. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM Calabretta B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562, 1991
22. Sambrook J, Fritsch EF, Maniatis F: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
23. Gao W-Y, Jaroszewski JW, Cohen JS, Cheng Y-C: Mechanisms of inhibition of herpes simplex virus type-2 growth by 28 mer phosphorothioate oligodeoxycytidine. J Biol Chem 265:20172, 1990
24. Tonkinson JL, Stein CA: Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res 22:4268, 1994
25. Besterman JM, Airhart JA, Woodworth RC, Low RB: Exocytosis of pinocytosed fluid in cultured cells: kinetic evidence for rapid turnover and compartmentation. J Cell Biol 91:716, 1981
26. Sutherland HJ, Eaves AC, Eaves CJ: Quantitative assays of human hemopoietic progenitor cells, in Gee AP (ed): Bone Marrow Processing and Purging: A Practical Guide. Boca Raton, FL, CRC, 1991, p 155
27. Maurer J, Janssen JWG, Thiel E, van Denderen J, Ludwig W-D, Aydemir Ü, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR: Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 337:1055, 1991
28. Lappalainen K, Urtti A, Söderling E, Jääskeläinen I, Syrjänen K, Syrjänen S: Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta 1196:201, 1994
29. Nestle FO, Mitra RS, Bennet CF, Chan H, Nickoloff BJ: Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103:569, 1994
30. Zhao Q, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM: Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 84:3660, 1994
31. Zhao Q, Song X, Waldschmidt T, Fisher E, Krieg AM: Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 88:1788, 1996
32. Jääskeläinen I, Mönkkönen J, Urtti A: Oligonucleotide-cationic liposome interactions. A physicochemical study. Biochim Biophys Acta 1195:115, 1994
33. Xu Y, Szoka FC Jr: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35:5616, 1996
34. Zelphati O, Szoka FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 93:11493, 1996
35. Di Giusto DL, Lee R, Moon J, Moss K, O'Toole T, Voytovich A, Webster D, Mule JJ: Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 87:1261, 1996
36. Kurzrock R, Guttermann JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990, 1988
37. Quattrone A, Papucci L, Schiavone N, Mini E, Capaccioli S: Intracellular enhancement of intact oligonucleotide steady-state levels by cationic lipids. Anti Cancer Drug Design 9:549, 1994
38. Maxfield FR: Weak bases and ionophores rapidly and reversibly raise the pH of endocytic vesicles in cultured mouse fibroblasts. J Cell Biol 95:676, 1982
39. Rädler JO, Koltover I, Salditt T, Safinya CR: Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packaging regimes. Science 275:810, 1997
40. Zabner J, Fasbender AJ, Moninger T, Poellinger K, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270:18997, 1995
41. Mislick KA, Baldeschwieler JD: Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci USA 93:12349, 1996
42. Ruoslahti E: Structure and biology of proteoglycans. Annu Rev Cell Biol 4:229, 1988
43. Stellrecht CM, Mars WM, Miwa Hiroshi, Beran M, Saunders GF: Expression pattern of a hematopoietic proteoglycan core protein gene during human hematopoiesis. Differentiation 48:127, 1991
44. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD: Transport from the plasma membrane via endosomes: Endocytosis, in: Molecular Biology of the Cell (ed 3). New York, NY, Garland, 1994, p 618
45. Iversen PL, Crouse D, Zon G, Perry G: Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res Dev 2:223, 1992
46. Balasubramaniam RP, Bennet MJ, Aberle AM, Malone JG, Nantz MH, Malone RW: Structural and functional analysis of cationic transfection lipids: The hydrophobic domain. Gene Therapy 3:163, 1996
47. Thierry AR, Dritschilo A: Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20:5691, 1992
48. RC5) cells. Antisense Res Dev 4:211, 1994
49. Nichols GL: Antisense oligonucleotides as therapeutic agents for chronic myelogenous leukemia. Antisense Res Dev 5:67, 1995
50. Käbisch A, Perenyi L, Seay U, Lohmeyer J, Pralle H: Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells. Acta Haematol 92:190, 1994
51. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the b2a2 junction. Exp Hematol 23:1606, 1995
52. Chasty R, Whetton A, Lucas G: A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Leuk Res 20:391, 1996
53. Smetsers TFCM, Linders EHP, van de Locht LTF, de Witte TM, Mensink EJBM: An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br J Haematol 96:377, 1997
54. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86:3891, 1995
55. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM: Acute-and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956, 1992
56. Tauchi T, Broxmeyer HE: BCR/ABL signal transduction. Int J Hematol 61:105, 1995